Last Updated: July 28, 2026

Drug Price Trends for CALCIUM ANTACID


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for CALCIUM ANTACID

Average Pharmacy Cost for CALCIUM ANTACID

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
CALCIUM ANTACID 500 MG CHW TAB 00536-1048-15 0.01709 EACH 2026-07-22
CALCIUM ANTACID 750 MG CHEW TAB 00536-1049-22 0.03227 EACH 2026-07-22
CALCIUM ANTACID 750 MG CHEW TAB 00536-1050-22 0.03227 EACH 2026-07-22
CALCIUM ANTACID 750 MG CHEW TAB 00536-1225-22 0.03227 EACH 2026-07-22
CALCIUM ANTACID 500 MG CHW TAB 00904-6412-92 0.01709 EACH 2026-07-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date
Last updated: February 14, 2026

How is the calcium antacid market positioned?

The calcium antacids market is characterized by steady demand driven by the prevalence of acid-related gastrointestinal conditions. These drugs serve as over-the-counter (OTC) remedies for indigestion, heartburn, and acid reflux. The segment's growth rate is influenced by increasing consumer awareness about gastrointestinal health, aging populations, and the prevalence of food habits that exacerbate acid issues.

What are the key manufacturers and their market shares?

Major manufacturers include:

  • GlaxoSmithKline: Produces Tums, a leading calcium carbonate-based antacid.
  • Bayer AG: Markets Alka-Seltzer, incorporating calcium carbonate.
  • Sanofi: Offers formulations including calcium-based antacids.
  • Reckitt Benckiser: Manufactures Gaviscon, with calcium carbonate options.

Market shares are segmented as follows (2022 estimates):

Company Market Share (%)
GlaxoSmithKline 45
Bayer AG 20
Sanofi 15
Reckitt Benckiser 10
Others 10

The market's consolidation status favors a few dominant players with established OTC distribution channels.

What are the current price points and cost dynamics?

Average retail price per 500 mg calcium carbonate tablet:

  • United States: $0.05 to $0.10
  • Europe: €0.04 to €0.09
  • Asia: $0.02 to $0.07

Bulk wholesale prices for manufacturers are significantly lower, approximately:

  • Per kilogram: $2 to $4, depending on purity and volume

Pricing is influenced by raw material costs (calcium carbonate), manufacturing scale, branding, and distribution expenses. Raw material costs account for approximately 30% of the manufacturing expenses.

What is the projected market size and growth?

The global calcium antacids market was valued at approximately $1.5 billion in 2022 and is projected to reach $2.1 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.2%.

Regional growth projections:

  • North America: CAGR of 3.8%
  • Europe: CAGR of 4.0%
  • Asia-Pacific: CAGR of 5.0%

Drivers include expanding middle-class populations, increased OTC drug consumption, and rising gastrointestinal health awareness.

How do regulatory and patent factors influence pricing?

Most calcium carbonate formulations are off-patent, which limits exclusive pricing power but encourages competition. Regulatory compliance costs (FDA and EMA approvals) are minimal due to established safety profiles. Market entry barriers are low, creating price competition pressure.

What are the potential innovations influencing future prices?

Innovation in formulation—for example, sustained-release versions or combination products—may command premium pricing. Development of new delivery systems, such as chewable or liquid formulations, can also impact prices.

What are the risks and opportunities for market players?

Risks:

  • Generic competition reducing margins
  • Regulatory changes affecting product formulations or labels
  • Raw material price volatility

Opportunities:

  • Expansion into emerging markets
  • Development of combination drugs for multiple gastrointestinal conditions
  • Brand differentiation through efficacy or convenience

How do price projections compare across regions?

Region 2022 Price Range (per 500 mg tablet) 2030 Projection CAGR (2022-2030)
United States $0.05–$0.10 $0.05–$0.12 4.1%
Europe €0.04–€0.09 €0.04–€0.11 4.2%
Asia-Pacific $0.02–$0.07 $0.03–$0.09 5.0%

Key Takeaways

  • The market primarily comprises OTC calcium carbonate formulations with high competition, limiting pricing power but offering consistent volume.
  • Price points in developed regions hover around $0.05 to $0.10 per tablet, with emerging markets showing lower prices but faster growth.
  • Future pricing trajectories hinge upon innovation, regional market expansion, and competitive dynamics.
  • Industry players should monitor raw material costs and regulatory landscapes to optimize margins.

FAQs

1. What factors influence the retail price of calcium antacids?
Raw material costs, manufacturing scale, branding strategies, distribution channels, and regional regulations.

2. How does patent status affect pricing strategies?
Most calcium carbonate formulations are off-patent, leading to increased competition and limited ability to set higher prices.

3. Which regions have the fastest growth potential?
The Asia-Pacific region exhibits the highest CAGR at approximately 5%, driven by rising healthcare awareness and expanding middle-class populations.

4. Are there opportunities for premium pricing?
Yes, via innovative formulations such as sustained-release or combination products targeting niche markets.

5. How do raw material costs impact profitability?
Raw calcium carbonate costs constitute roughly 30% of manufacturing expenses; fluctuations can significantly affect margins.


Sources:

[1] MarketWatch, “Calcium Carbonate Market Size, Share & Trends Analysis,” 2022.
[2] Allied Market Research, “Over-the-Counter Drugs Market Forecast,” 2022.
[3] Fact.MR, “Global Antacids Market Report,” 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.